{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:15:43Z","timestamp":1764688543549},"reference-count":30,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2006,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            A randomized, double-blind, double-dummy trial was performed comparing 200 mg of cefditoren-pivoxil twice daily for 5 days versus standard cefuroxime-axetil treatment (250 mg twice daily for 10 days) of Anthonisen type I or II acute exacerbations of chronic bronchitis. The modified intention-to-treat population included 541 patients. Patients were assessed during therapy, at the end of therapy (visit 3; primary evaluation time point), and at follow-up. Clinical success was obtained in 79.9% of the 264 patients included in the cefditoren-pivoxil group and in 82.7% of the 277 patients in the cefuroxime-axetil group (treatment difference, 95% confidence interval [CI]: \u22122.8, \u22129.7 to 3.6%). Treatment clinical effects were more clearly seen in sputum signs (decreasing volume and purulence from approximately 80% to approximately 10% of the patients). At the end of treatment, exploratory analysis of the per-pathogen bacteriological response showed 72.8% (of 103 isolates) in the cefditoren-pivoxil arm versus 67.0% (of 94 isolates) in the cefuroxime-axetil group (treatment difference; 95% CI: 5.8, \u22127.0 to 18.6%). Globally, the per-pathogen bacteriological response correlated well with clinical success: 83.5% of 164 baseline isolates from patients with a clinical success were eradicated or presumably eradicated, in contrast to only 3% of 33 isolates from patients with a clinical failure. Clinical success in patients infected with\n            <jats:italic>Haemophilus influenzae<\/jats:italic>\n            , the most frequent isolate, was 84% (of 50) and 82.5% (of 40) (treatment difference; 95% CI: 1.5, \u221214 to 17%) in the cefditoren-pivoxil versus the cefuroxime-axetil group. Although this study does not prove that either drug is better than a placebo, cefditoren-pivoxil and the standard 10-day cefuroxime-axetil course had similar point estimates of success in acute exacerbations of chronic bronchitis.\n          <\/jats:p>","DOI":"10.1128\/aac.50.5.1762-1767.2006","type":"journal-article","created":{"date-parts":[[2006,4,26]],"date-time":"2006-04-26T22:58:47Z","timestamp":1146092327000},"page":"1762-1767","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":33,"title":["Clinical and Bacteriological Efficacy in Treatment of Acute Exacerbations of Chronic Bronchitis with Cefditoren-Pivoxil versus Cefuroxime-Axetil"],"prefix":"10.1128","volume":"50","author":[{"given":"Jose-Luis","family":"Alvarez-Sala","sequence":"first","affiliation":[{"name":"Pneumology Department, Hospital Clinico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kardos","sequence":"additional","affiliation":[{"name":"Group Practice and Centre for Allergy, Respiratory and Sleep Medicine, Red Cross Maingau Hospital, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesu\u0301s","family":"Marti\u0301nez-Beltra\u0301n","sequence":"additional","affiliation":[{"name":"Microbiology Department, Hospital Ramo\u0301n y Cajal, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Coronel","sequence":"additional","affiliation":[{"name":"Scientific Department, Tedec-Meiji Farma, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Aguilar","sequence":"additional","affiliation":[{"name":"Microbiology Department, School of Medicine, Universidad Complutense, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Cefditoren AECB Working Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-106-2-196"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.02.017"},{"key":"e_1_3_2_4_2","first-page":"31","volume":"49","year":"2002","unstructured":"Ball, P., F. Baquero, O. Cars, T. File, J. Garau, K. Klugman, D. E. Low, E. Rubinstein, R. Wise, and the Consensus Group on Resistance and Prescribing in Respiratory Tract Infection. 2002. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J. Antimicrob. Chemother.49:31-40.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.3_Supplement.199S"},{"key":"e_1_3_2_6_2","first-page":"317","volume":"17","year":"2004","unstructured":"Barber\u00e1n, J., M. J. Gim\u00e9nez, L. Aguilar, and J. Prieto. 2004. Evidencia cient\u00edfica y concepci\u00f3n global del tratamiento emp\u00edrico de la infecci\u00f3n de v\u00edas respiratorias bajas en la comunidad. Rev. Esp. Quimioter.17:317-324.","journal-title":"Rev. Esp. Quimioter."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780091208"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.1.159-164.2002"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh375"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.5.767"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.112.6_Supplement.310S"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(98)00008-9"},{"key":"e_1_3_2_14_2","first-page":"465","volume":"113","year":"1976","unstructured":"Gump, D. W., C. A. Phillips, B. R. Forsyth, K. McIntosh, K. R. Lamborn, and W. H. Stouch. 1976. Role of infection in chronic bronchitis. Am. Rev. Respir. Dis.113:465-474.","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_3_2_15_2","first-page":"7","volume":"10","year":"1992","unstructured":"Jorgensen, A. F., J. Coolidge, P. A. Pedersen, K. P. Petersen, S. Waldorff, and E. Widding. 1992. Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis. A double-blind, placebo-controlled multicentre study in general practice. Scand. J. Prim. Health Care10:7-11.","journal-title":"Scand. J. Prim. Health Care"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11081-9"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.121.5.1449"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.suppl_2.25"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.163.5.2101039"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.suppl_2.19"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1965-1972.2005"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)01025-7"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520360071042"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.153-160.2005"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012561"},{"key":"e_1_3_2_26_2","first-page":"6","volume":"5","year":"2004","unstructured":"Soriano, F. 2004. Importancia de los par\u00e1metros farmacocin\u00e9ticos y farmacodin\u00e1micos en la elecci\u00f3n del tratamiento antimicrobiano de la infecci\u00f3n respiratoria. Med. Clin. Monogr. (Barcelona)5:6-11.","journal-title":"Med. Clin. Monogr. (Barcelona)"},{"key":"e_1_3_2_27_2","first-page":"296","volume":"23","year":"2004","unstructured":"Soriano, F., J. J. Granizo, P. Coronel, M. Gimeno, E. Rodenas, M. Gracia, C. Garcia, R. Fernandez-Roblas, J. Esteban, and I. Gadea. 2004. Antimicrobial susceptibility of Haemophilus influenzae,Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries. The ARISE project. Int. J. Antimicrob. Agents23:296-299.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2003.15.2.107"},{"key":"e_1_3_2_29_2","first-page":"37","volume":"5","year":"2004","unstructured":"Torres, A. 2004. Tratamiento antibi\u00f3tico de las agudizaciones de la enfermedad pulmonar obstructiva cr\u00f3nica. Papel de la nueva formulaci\u00f3n de liberaci\u00f3n prolongada de amoxicilina-\u00e1cido clavul\u00e1nico 2.000\/125 mg. Med. Clin. Monogr. (Barcelona)5:37-41.","journal-title":"Med. Clin. Monogr. (Barcelona)"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464220-00009"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.125.3.953"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.50.5.1762-1767.2006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.50.5.1762-1767.2006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:02:34Z","timestamp":1645470154000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.50.5.1762-1767.2006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["10.1128\/AAC.50.5.1762-1767.2006"],"URL":"https:\/\/doi.org\/10.1128\/aac.50.5.1762-1767.2006","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2006,5]]},"assertion":[{"value":"2005-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-03-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}